Cancer Research UK

Cancer Grand Challenges announces five new teams taking on cancer’s toughest challenges

Retrieved on: 
Wednesday, March 6, 2024

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.
  • These include the Scientific Foundation of the Spanish Association Against Cancer, the Bowelbabe Fund for Cancer Research UK, Institut National Du Cancer, the Dutch Cancer Society, The Mark Foundation for Cancer Research and KiKa (Children Cancer Free Foundation).
  • “Together with our network of visionary partners and research leaders, Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines and aims to overcome cancer’s toughest problems,” said Dr. David Scott, Director of Cancer Grand Challenges.
  • The Cancer Grand Challenges community has grown to more than 1,200 investigators and collaborators with 16 teams from across the world taking on 13 challenges.

Team SAMBAI, TOUCH, The Black Breast Cancer Alliance, Named As Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.
  • TOUCH, The Black Breast Cancer Alliance, as part of Team SAMBAI, is the first U.S.
  • Black-led breast cancer advocacy group to be an integral partner in the international Cancer Grand Challenge study.
  • Inequities in cancer prevention, screening, and treatment lead to disparities in cancer incidence and mortality and are a significant public health concern.

Team SAMBAI, Yemaachi Biotech, Named as Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024

Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.

Key Points: 
  • Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.
  • “We are confident that this work will be fruitful and will contribute to innovations that will benefit patients globally.
  • We are honored by Team SAMBAI’s belief in our scientific work and impact-driven mission.”
    Inequities in cancer prevention, screening, diagnosis, treatment, and research lead to disparities in cancer incidence and mortality and are a major public health concern.
  • Cancer Grand Challenges is a global funding initiative, co-founded by Cancer Research UK and the National Cancer Institute in the US, that supports a community of diverse, global teams to come together, think differently and take on cancer’s toughest challenges.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies

Retrieved on: 
Wednesday, February 21, 2024

Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.
  • This trial is evaluating the Company’s first-in-class biologic CAR T-Cell Engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
  • View the full release here: https://www.businesswire.com/news/home/20240221259676/en/
    Cancer Research UK’s Centre for Drug Development is sponsoring and conducting the Phase 1/2 clinical trial of ALETA-001, the lead agent in Aleta's portfolio.
  • Clinical evaluation of ALETA-001 is a key milestone toward a much-needed treatment option for the many cancer patients whose CD19-targeted CAR T-cell therapies ultimately stop working.

International Team Led by CHOP Cancer Expert Receives Multimillion Dollar Grant for Childhood Cancer Research from Cancer Grand Challenges

Retrieved on: 
Wednesday, March 6, 2024

PHILADELPHIA, March 6, 2024 /PRNewswire/ -- An interdisciplinary, global team of scientists led by Yael Mossé, MD, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia (CHOP), has been selected as one of five research teams from all over the world to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK. Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.

Key Points: 
  • Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.
  • Last year, 176 global teams submitted bold ideas for tackling some of the most pressing challenges in cancer research and care.
  • The National Cancer Institute and Cancer Research UK, the world's leading funders of cancer research, co-founded and launched the Cancer Grand Challenges initiative in 2020.
  • In addition to the Team KOODAC3 award, Team MATCHMAKERS, which includes Dr. Nikolaos G. Sgourakis from CHOP, also received a Cancer Grand Challenges award of up to $25 million.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Multi-cancer early detection tests: a simple blood test has the potential to revolutionise cancer screening

Retrieved on: 
Monday, February 5, 2024

Swiss Re Institute's new report "Multi-Cancer Early Detection: cancer screening beyond today's boundaries", explores the future risks and opportunities for patients and insurers.

Key Points: 
  • Swiss Re Institute's new report "Multi-Cancer Early Detection: cancer screening beyond today's boundaries", explores the future risks and opportunities for patients and insurers.
  • However, given this early stage of their development, we need to carefully examine their potential, their risks, and the implications for insurers."
  • MCED blood tests are a type of liquid biopsy which can detect cancer biomarkers in a single sample of blood.
  • How to order this study:
    You can download "Multi-Cancer Early Detection: cancer screening beyond today's boundaries" here .

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

Retrieved on: 
Friday, November 10, 2023

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.
  • Lean, go-to-market commercial model, well positioned to scale rapidly to generate significant value from Japan and APAC (ex-China) geographic expansion.
  • Note regarding the Idorsia transaction: the quarter ended 30 September 2023 (Q3 2023) is the first period in which the Group has consolidated the financial results of Idorsia’s former Japanese and South Korean businesses.
  • Revenue totalled JPY 5,474 million (US$39.6 million*), a decrease of JPY 3,167 million (US$27.9 million) vs. the prior corresponding period.

Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities

Retrieved on: 
Monday, December 4, 2023

Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.

Key Points: 
  • Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.
  • The agreement will enable the parties to discuss opportunities for collaboration to support the charity’s research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development.
  • This includes the DETERMINE trial – the first UK national precision medicine trial in rare cancers, and other Cancer Research UK and Cancer Research Horizons research collaborations.
  • Additional potential collaboration activities may include sharing data and samples from the Cancer Research UK-funded research network to further develop and validate Guardant’s technologies, as well as explore other projects to accelerate the discovery and development of cancer drugs and diagnostics.

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

Retrieved on: 
Monday, December 4, 2023

NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.

Key Points: 
  • NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
  • This published report informs UK doctors, patients, and other interested parties that NICE has started the review of Multikine and is soliciting public comment.
  • The NICE briefing includes the following statements:
    “The current standard of care for locally advanced SCCHN is an aggressive combined modality therapy.
  • According to Cancer Research UK , an average of 12,400 cases of head and neck cancer are diagnosed each year in the UK.